DXRNasdaqFiscal year ends December 31
DAXOR CORP
Financials through Q4 FY2011, quarter ended Dec 31, 2011
$9.84−0.21 (-2.09%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- 2.54%
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Daxor has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Daxor filed with the SEC
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System
Other events · EX-99.1 to Form 8-K
Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
Other events · EX-99.1 to Form 8-K
Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer
Other events · EX-99.1 to Form 8-K
Corporation Announces Closing of $4.0 Million Underwritten Public Offering
Other events · EX-99.1 to Form 8-K
Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option
Other events · EX-99.1 to Form 8-K
Corporation Commences Trading on The NASDAQ Capital Market
Other events · EX-99.1 to Form 8-K